Guidelines for the management of haemophilia in Australia
The Guidelines for the management of haemophilia in Australia were available for comment during a six-week open public consultation process from Wednesday 11 November 2015 – Wednesday 23 December 2015. All submissions are being reviewed by the Australian Haemophilia Centre Directors’ Organisation and the guidelines will be amended accordingly. The guidelines are expected to be released by 30 June 2016.
Any enquiries relating to the development of the guidelines can be emailed to haemophilia.guidelines [at] blood.gov.au.
Patient Blood Management Guidelines: Module 6 Neonatal and Paediatric
The Patient Blood Management Guidelines: Module 6 Neonatal and Paediatric was open for public consultation from Monday 31 August 2015 – Friday 23 October 2015. All submissions will be reviewed by the Clinical/Consumer Reference Group, which comprises representatives from specialist colleges, societies and organisations. Following that, the draft module will be submitted to the NHMRC Council for approval.
Further updates regarding the release of the Patient Blood Management Guidelines: Module 6 Neonatal and Paediatrics will be provided at www.blood.gov.au/pbm-guidelines.
Imported Plasma and Recombinant Product - Supply Contracts
Public consultation on the Imported Plasma and Recombinant Product supply contracts closed on 22 July 2015 at 10:00am. The NBA issued an industry Request for Information (RFI) and stakeholder consultation paper seeking information to inform future supply arrangements. Due the commercial nature of the information submitted in response to the RFI and stakeholder consultation paper a detailed summary is not available.
Proposed changes to the Criteria for the clinical use of immunoglobulin in Australia
Public consultation on the proposed changes to the Criteria for the clinical use of immunoglobulin in Australia closed at 5pm on Monday 27 July 2015. The Specialist Working Groups reviewed all submissions and revised the Criteria as necessary before submission to the National Immunoglobulin Governance Advisory Committee (NIGAC) in November. NIGAC has endorsed the changes which will now be presented to the Jurisdictional Blood Committee (JBC)for endorsement.
Please note, if endorsed by JBC, changes to the Criteria will be implemented as a staged approach following full national rollout of BloodSTAR (System for Tracking Authorisations and Reviews) in 2016. The NBA will develop a transition plan and communications plan to support implementation, which will be communicated broadly to all key stakeholders at the appropriate time.
The response to the feedback and proposed medical condition pro forma documents have been published on the NBA website and are available here for your information.
If you have any questions or concerns please contact the Ig Governance Project Director Melody Black on 02 6151 5031 or IgGovernance [at] blood.gov.au